Milton S. Hershey Medical Center
l u Q in
To explore how estrogen deficiency impacts the blood pressure (BP) and sympathetic nerve activity (SNA), and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It is hypothesized that estrogen deficiency increases BP, SNA and the pathway activities of the key pro-inflammatory mediators. Those effects are impacted through the downregulation of the estrogen receptor.
Postmenopausal Symptoms
Cardiovascular Diseases
Placebo
Estradiol
EARLY_PHASE1
In the United States, cardiovascular disease (CVD) is one of the major health concerns and affects approximately 6.5 million people over 40. As the number of elderly women increases, CVD becomes an increasing problem. Estrogen is cardioprotective, and the menopause condition in the aging female population induces the loss of this protective effect. There has been a dilemma for medical treatment in CVD patients with comorbidities including endometriosis or breast cancer history. Overall, these patients lose the cardioprotective effect of estrogen and increase the risk of CVD development. However, there is still little understanding regarding the mechanism for how estrogen suppression in women accelerates CVD development. The proposed studies are, therefore, the essential first step to elucidating how estrogen alters mechanisms underlying CVD and provide the preclinical data to design studies for future alternative intervention strategies for CVD patients undergoing estrogen suppression therapies.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 20 participants |
Masking : | TRIPLE |
Primary Purpose : | BASIC_SCIENCE |
Official Title : | Estrogen Deficiency on Cardiovascular Risk: Sympathetic Responses and Pro-inflammatory Cytokines |
Actual Study Start Date : | 2025-09 |
Estimated Primary Completion Date : | 2027-09 |
Estimated Study Completion Date : | 2027-11 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 54 Years to 75 Years |
Sexes Eligible for Study: | FEMALE |
Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
No Location Found